Goldman Sachs analyst Chris Shibutani adjusted the price target for Merck (NSE:PROR) & Co. Inc. (NYSE:MRK) to $129.00, down from the previous $135.00, while reiterating a Buy rating on the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

The stock markets in the US opened higher on February 4 as investors remained cautious about China’s stance on the Trump tariffs. Salesforce shares were trading 1.64% higher in the early market ...

AMD is shipping more desktop chips to keep up with the demand as the Ryzen 9800X3D remains hard to find in stock.

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

Gardasil shipment pause, weak guidance, and looming Keytruda risks send investors scrambling--can Merck turn things around?

The Nasdaq Composite and S&P 500 rose on Tuesday due to strong gains from Palantir as market focused on latest trade news.